Financial Report: Genzyme 4Q

Genzyme

4Q Revenues: $1.2 billion (+13%)

4Q Earnings: $86.7 million (+10%)

FY Revenues: $4.6 billion (+21%)

FY Earnings: $421.1 million (-12%)

Comments: Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%). Aldurazyme sales were $38 million in the quarter (+9%) and $152 million for the year (+23%). Revenue from the Cardiometabolic and Renal segment was $956 million in 2008 (+15%). Sales of sevelamer were $169 million in the quarter (+2%) and $678 million for the year (+13%). Sales of Thyrogen were up 20% in the quarter to $37 million and up 31% for the year to $149 million. For the year, hematologic oncology segment revenue was up 52% to $117 million, and in the quarter was $36 million (+59%). In the quarter, the FDA approved Mozobil for autologous stem cell transplants in non-Hodgkin’s lymphoma and multiple myeloma patients. EU approval is expected in the first half of this year.